Performance was driven by strong execution across the specialty pharmaceutical platform, particularly within health systems and physician practices. The MSO platform, including OneOncology and Retina Consultants of America (RCA), performed ahead of expectations, benefiting from the ability to attract physicians to the network. Management attributed double-digit organic operating income growth in the U.S. to underlying specialty strength, even when excluding the OneOncology acquisition and a prior customer loss. Digital transformation efforts, including AI-driven demand forecasting, are being utilized to improve product availability and reduce manual operational processes. The value proposition remains resilient despite manufacturer list price reductions, which acted as a $2.4 billion headwind to revenue but did not derail profit growth.